Publications by authors named "Charlene Duboc"

Claim this Profile
T
The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Cécile Pétigny-Lechartier, Charlène Duboc, Abdelghani Jebahi, Marie-Hélène Louis, Edwige Abeilard

Mol Cancer Ther· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis